PennyStockChief.com is the #1 leader for breaking news, offering quality reports to investors looking for the most undervalued companies in the market. The chief provides its subscribers with timely information and exclusive analysis on U.S. companies with substantial upside potential. The Chief is issuing reports on the following equities:

Centaurus Diamond Technology (OTCBB: CTDT), Apple Inc. (NASDAQ: AAPL), Human Genome Sciences Inc (NASDAQ: HGSI), Mattel Inc (NASDAQ: MAT)

Centaurus Diamond Technology (OTCBB: CTDT)

CTDT is pleased to announce that it has signed an agreement with Tabco Products Inc. ("Tabco") for the development of its unique Centaurus' Magnatech Diamond Technology process. This patented technology enables the production of "cultured" diamonds that are chemically, atomically and structurally identical to natural diamonds. Centaurus' unique process applies a collapsing magnetic field to a carbon sample thereby changing its crystalline structure to that of a diamond.

For Free Trend Analysis Report here: http://pennystockchief.com/ticker.php?ticker=CTDT

Apple Inc. (NASDAQ: AAPL)

AAPL is currently down $2.47(.40%). Open price of $610.79 and hitting a high of $611.50. Could the new product features send the stock to higher levels?

For Free Trading Analysis Report Here: http://pennystockchief.com/ticker.php?ticker=AAPL

Human Genome Sciences Inc (NASDAQ: HGSI)

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Human Genome Sciences ("HGSI") (NASDAQ: HGSI) to GlaxoSmithKline plc for shareholders. Under the proposed transaction, HGSI shareholders will only receive $14.25 in cash for each share of HGSI stock owned, well below the 52 week high of $23.84.

For Free Trading Analysis Report Here and more information on the investigation: http://pennystockchief.com/ticker.php?ticker=HGSI

Mattel Inc (NASDAQ: MAT)

Today, MAT reported 2012 second quarter financial results. For the quarter, the Company reported net income of $96.2 million, or $0.28 per share, compared to last year's second quarter net income of $80.5 million, or $0.23 per share.

For Free Trading Analyisis Report Here: http://pennystockchief.com/ticker.php?ticker=MAT

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO NewsWire one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

IO NewsWire editor@ionewswire.com

Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Human Genome Sciences
Grafico Azioni Human Genome Sciences (NASDAQ:HGSI)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Human Genome Sciences